Hexarelin Blood Work Before & After — Lab Testing Guide

Most protocols for hexarelin research fail at the monitoring stage, not the dosing stage. Researchers initiate peptide administration without establishing baseline pituitary hormone levels, then wonder weeks later whether the compound is producing a meaningful growth hormone response or simply elevating cortisol and prolactin without therapeutic benefit. The difference between a well-documented research protocol and guesswork comes down to three lab panels. One before, one at week four, and one at week eight.

Our team has worked with research institutions evaluating hexarelin's effects on the growth hormone axis for over a decade. The gap between doing hexarelin blood work labs correctly and wasting time on incomplete data is narrower than most researchers assume. It's entirely about timing, marker selection, and knowing which deviations signal mechanism confirmation versus adverse pituitary disruption.

What blood work labs should be checked before and after using hexarelin?

Before initiating hexarelin, baseline labs must include IGF-1, cortisol (AM fasting), prolactin, fasting glucose, and HbA1c. Post-administration labs at four and eight weeks should repeat IGF-1, cortisol, and prolactin to confirm growth hormone axis response and rule out pituitary desensitisation. Hexarelin stimulates growth hormone release via ghrelin receptor agonism, but also triggers cortisol and prolactin elevation. Monitoring both therapeutic and counter-regulatory hormones is essential to distinguish productive GH pulsatility from non-selective pituitary activation.

Hexarelin differs from other growth hormone secretagogues in one critical way: it produces the strongest acute GH pulse of any peptide in this class, but also the fastest receptor desensitisation. Without serial IGF-1 tracking, researchers miss the point at which pulsatile benefit plateaus. Typically around week six in continuous daily dosing protocols. The rest of this guide covers exactly which labs to order before starting hexarelin, when to retest during the protocol, and what numerical changes confirm the peptide is working versus when it signals pituitary fatigue or metabolic disruption.

Pre-Administration Baseline Panel: The Five Essential Markers

The hexarelin blood work labs panel begins with five biomarkers measured at baseline. Before the first dose is administered. These establish the reference range against which all post-treatment changes are compared. IGF-1 (insulin-like growth factor 1) is the primary endpoint because it reflects integrated 24-hour growth hormone secretion. Direct GH measurement is unreliable in research protocols due to its pulsatile nature. Serum GH fluctuates every 90–180 minutes, making single time-point sampling nearly meaningless. IGF-1, synthesised in the liver in response to sustained GH exposure, provides a stable surrogate marker. Baseline IGF-1 should be drawn fasting, ideally between 7–9 AM to control for diurnal variation.

Cortisol must be measured simultaneously because hexarelin is a non-selective ghrelin receptor agonist. It binds GHS-R1a receptors not only in the pituitary (triggering GH release) but also in the hypothalamus and adrenal axis (elevating ACTH and cortisol). Morning fasting cortisol establishes whether the subject has pre-existing hypothalamic-pituitary-adrenal axis dysregulation. Values above 20 mcg/dL at baseline suggest the subject may experience exaggerated cortisol responses to hexarelin, which can blunt anabolic signaling despite elevated GH. Prolactin is the third critical marker. Hexarelin consistently raises prolactin alongside GH, and baseline prolactin above 25 ng/mL in males or 30 ng/mL in females indicates the subject should not initiate the protocol without further endocrine evaluation.

Fasting glucose and HbA1c complete the pre-administration panel. Hexarelin transiently suppresses insulin secretion during the acute GH pulse, then stimulates compensatory hyperinsulinemia in the post-pulse recovery phase. Subjects with baseline fasting glucose above 100 mg/dL or HbA1c above 5.7% are at higher risk for glucose dysregulation during extended protocols. Our experience shows that researchers who skip baseline glucose markers consistently misattribute metabolic changes to diet or training variables when the root cause is peptide-induced insulin resistance.

Week Four and Week Eight Follow-Up: Tracking Pituitary Response and Desensitisation

The second hexarelin blood work labs panel occurs at week four. The point at which continuous daily dosing typically begins to show diminishing IGF-1 elevation despite unchanged dose. Repeat IGF-1, cortisol, and prolactin at this checkpoint. IGF-1 should have increased by 25–50% from baseline if the peptide is producing sustained GH pulsatility. Anything less suggests inadequate dosing or early receptor downregulation. Cortisol elevation above 30% from baseline without proportional IGF-1 increase is a red flag: the peptide is activating the HPA axis without corresponding GH release, which compounds catabolic signaling and defeats the research objective.

Week eight is the critical decision point. If IGF-1 has plateaued or declined from the week four peak, receptor desensitisation has occurred. Continuing daily dosing beyond this point yields minimal additional benefit. The standard mitigation is dose cycling: five days on, two days off, which allows ghrelin receptor resensitisation. Prolactin should remain within 50% of baseline at week eight; values exceeding double the baseline level indicate non-selective pituitary activation and warrant protocol suspension. Fasting glucose and HbA1c should be rechecked at week eight in any subject whose baseline values were above optimal range. HbA1c increases of 0.3% or more signal that insulin resistance is outpacing any anabolic benefit from GH.

One mistake researchers consistently make: they retest too early or too late. IGF-1 peaks 48–72 hours after the final hexarelin dose in most protocols. Drawing labs on the same day as dosing captures the acute GH pulse, not the sustained elevation that reflects cumulative effect. We schedule all follow-up labs 72 hours post-dose to isolate baseline-shifted IGF-1 from transient spikes.

Hexarelin Blood Work Labs: Pre-Dose vs Post-Dose Comparison

This table isolates the numerical thresholds that distinguish productive hexarelin response from counter-regulatory hormone dominance. IGF-1 elevation without proportional cortisol or prolactin increase is the ideal outcome. It confirms selective GH axis activation. Cortisol rising faster than IGF-1 is the failure mode most researchers encounter but fail to recognize without serial testing.

What If: Hexarelin Lab Monitoring Scenarios

What If IGF-1 Doesn't Increase After Four Weeks?

Increase the dose by 50 mcg and retest at week six. Lack of IGF-1 response usually reflects underdosing, not non-responsiveness. Hexarelin's effective range is 100–200 mcg per dose for most research models. If IGF-1 remains unchanged at week six despite dose escalation, the peptide is either degraded (improper storage), the subject has pre-existing GH resistance (rare), or the dosing schedule conflicts with endogenous GH pulses. Hexarelin works best when administered during natural GH troughs. Late morning or early afternoon, not immediately pre-sleep when endogenous nocturnal GH is already elevated.

What If Cortisol Rises Significantly But IGF-1 Stays Flat?

Suspend the protocol immediately and allow a two-week washout. This pattern. Elevated cortisol without IGF-1 increase. Indicates the peptide is activating ACTH release without corresponding somatotroph (GH-secreting cell) stimulation. It's the worst possible outcome: catabolic hormone elevation without anabolic benefit. Reintroduce hexarelin at 50% of the previous dose after washout, administered in a pulsed schedule (every other day) rather than daily. Some research models respond better to intermittent dosing because it prevents hypothalamic feedback suppression that blunts GH release during continuous exposure.

What If Prolactin Doubles at Week Four?

Reduce dose by 30–40% and switch to an every-other-day schedule. Prolactin elevation is dose-dependent. Cutting dose while maintaining pulsatile administration often restores the IGF-1 response without further prolactin increase. If prolactin remains doubled at week six despite dose reduction, discontinue hexarelin and substitute a more selective GHS like CJC1295 Ipamorelin 5MG 5MG, which produces GH pulsatility without the prolactin surge that hexarelin triggers.

The Unfiltered Truth About Hexarelin Monitoring

Here's the honest answer: most researchers don't run the hexarelin blood work labs they should because they assume the peptide 'works' based on subjective changes. Perceived recovery improvement, slight body composition shifts, or training volume tolerance. None of those observations confirm growth hormone axis activation. Hexarelin raises cortisol and prolactin in every subject. The question is whether it's also raising GH enough to justify those counter-regulatory hormone increases. Without serial IGF-1 testing, you're guessing. The peptide might be producing a strong acute GH pulse immediately post-injection, but if receptor desensitisation has occurred by week five, you're administering a compound that elevates stress hormones daily with zero sustained anabolic benefit. That's not research. It's expensive placebo administration with metabolic side effects.

The second uncomfortable truth: hexarelin is the least forgiving peptide in this class for dosing errors. Hexarelin produces the highest peak GH output of any growth hormone secretagogue, but it also desensitises ghrelin receptors faster than GHRP-2, GHRP-6, or ipamorelin. If your protocol doesn't include planned dose cycling or periodic washouts, you'll hit a wall around week six where IGF-1 stops rising despite continued dosing. The only way to detect that wall before wasting another month is to run the week four and week eight labs. Skipping them doesn't save money. It guarantees you'll spend more on wasted peptide doses that aren't producing the response you assume they are.

Storage and Handling Impact on Lab Results

One variable researchers consistently overlook when interpreting hexarelin blood work labs: peptide degradation from improper storage directly affects biomarker response. Hexarelin is supplied as lyophilised powder and must be stored at −20°C before reconstitution. Once reconstituted with bacteriostatic water, it must be refrigerated at 2–8°C and used within 28 days. Any temperature excursion above 8°C causes irreversible structural degradation. A vial exposed to room temperature for six hours may appear unchanged visually, but the peptide's ability to bind ghrelin receptors and stimulate GH release is compromised. If your week four labs show no IGF-1 increase despite proper dosing, verify storage conditions before assuming the subject is non-responsive.

Our team sources all research peptides from suppliers with third-party purity verification and cold-chain shipping documentation. Real Peptides manufactures every compound through small-batch synthesis with exact amino-acid sequencing, guaranteeing structural integrity at the point of delivery. Storage after that point is the researcher's responsibility. Even high-purity hexarelin loses potency if handled incorrectly. When labs don't match expected outcomes, storage failure is the first variable to rule out, not the last.

Hexarelin blood work labs aren't optional add-ons to a research protocol. They're the core documentation that proves the peptide is producing the intended pituitary response. IGF-1, cortisol, and prolactin at baseline, week four, and week eight provide the only objective evidence that hexarelin is raising growth hormone without disproportionately activating counter-regulatory pathways. Without those three checkpoints, you're running a subjective observation protocol, not a controlled research study.